Healthcare Purchasing News
  • Magazine
  • Continuing Education
  • Webinars
  • Whitepapers
  • Videos
  • Events
  • Hall of Fame
  • Advertise
  • Source Guide
  • Subscribe
  • Sourcing & Logistics
  • Sterile Processing
  • Surgical & Critical Care
  • Patient Satisfaction
  • Infection Prevention
  • EVS & Facility Services
  • Healthcare IT
  • Regulatory
  • Topics
    Sourcing & LogisticsSterile ProcessingSurgical & Critical CarePatient SatisfactionInfection PreventionEVS & Facility ServicesHealthcare ITRegulatory
    Resources
    HPN Source GuideContinuing EducationWebinarsWhitepapersVideosEventsHall of FameAdvertiseAd Specs
    User Tools
    SubscribeContact UsAbout UseNewsletterMagazinesPrivacy PolicyTerms & Conditions
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    1. Infection Prevention

    Moderna submits application to the FDA for full approval of their COVID-19 vaccine

    Aug. 27, 2021
    Photo by Towfiqu barbhuiya on Unsplash
    Towfiqu Barbhuiya Hft V5 Xp2lk I Unsplash

    Moderna has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the full licensure of the Moderna COVID-19 Vaccine for active immunization to prevent COVID-19 in individuals 18 years of age and older. As part of the completed BLA submission, Moderna has requested Priority Review.

    Moderna began the submission process in June, which applies specifically to use of the vaccine in people 18 years of age and older.

    The completed submission includes clinical data from the Phase 3 COVE study of the Moderna COVID-19 vaccine, which enrolled more than 30,000 participants in the U.S. and was conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the Department of Health and Human Services.

    In the final analysis of Phase 3 COVE study data, the Moderna COVID-19 vaccine showed 93% efficacy, which remained durable through six months after administration of the second dose.

    Moderna has also filed for an emergency use authorization (EUA) for the use of its vaccine in adolescents ages 12 and above with the U.S. FDA.

    Moderna release

    More on COVID

    Latest in Infection Prevention

    1200085423 © deepblue4you | gettyimages.com
    Infection Prevention

    Sanford Health’s Instrument Quality Conundrum

    Janette Wider
    Nov. 28, 2023
    Photo 197864141 © Dizain777 | Dreamstime.com
    Infection Prevention

    WHO sees Uptick of Respiratory Illnesses in Children in Northern China

    Nov. 27, 2023
    Photo 117616099 | Antimicrobial Resistance © Designer491 | Dreamstime.com
    Infection Prevention

    IDSA announces Antimicrobial Stewardship Centers of Excellence designation recipients

    Janette Wider
    Nov. 21, 2023
    Photo 32161147 © Fasphotographic | Dreamstime.com
    Infection Prevention

    Global measles threat continues to grow as another year passes with millions of children unvaccinated

    Nov. 21, 2023
    Photo 281959520 © Zelwanka | Dreamstime.com
    Infection Prevention

    Expedited availability of additional doses of new RSV immunization for infants

    Nov. 20, 2023
    Healthcare Purchasing News
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo